Inovio Pharmaceuticals Announces 1-4 Reverse Split for INO Stock
It has not said when the split will take effect
On Friday, Inovio Pharmaceuticals (INO) announced that its shareholders had approved 1-for-4 reverse stock split of Inovio common stock. INO shares sank more than 5% in morning trading.
Inovio said that the effective date of the reverse stock split would be disclosed at a future date after Inovio complies with “standard NYSE administrative processes.”
In a statement, Inovio President and CEO Dr. J. Joseph Kim said: “Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.”
Inovio is developing vaccines against HPV-caused pre-cancers and cancers, prostate, breast, and lung cancers, and HIV, influenza, malaria and hepatitis.
More Pharma Stock News:
Article printed from InvestorPlace Media, http://investorplace.com/2014/05/inovio-pharmaceuticals-announces-1-4-reverse-split-ino-stock/.
©2017 InvestorPlace Media, LLC